Literature DB >> 16628198

Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome.

Pascal Descargues1, Céline Deraison, Catherine Prost, Sylvie Fraitag, Juliette Mazereeuw-Hautier, Marina D'Alessio, Akemi Ishida-Yamamoto, Christine Bodemer, Giovanna Zambruno, Alain Hovnanian.   

Abstract

SPINK5 (serine protease inhibitor Kazal-type 5), encoding the protease inhibitor LEKTI (lympho-epithelial Kazal-type related inhibitor), is the defective gene in Netherton syndrome (NS), a severe inherited keratinizing disorder. We have recently demonstrated epidermal protease hyperactivity in Spink5(-/-) mice resulting in desmosomal protein degradation. Herein, we investigated the molecular mechanism underlying the epidermal defect in 15 patients with NS. We demonstrated that, in a majority of patients, desmoglein 1 (Dsg1) and desmocollin 1 (Dsc1) were dramatically reduced in the upper most living layers of the epidermis. These defects were associated with premature degradation of corneodesmosomes. Stratum corneum tryptic enzyme (SCTE)-like and stratum corneum chymotryptic enzyme (SCCE)-like activities were increased, suggesting that these proteases participate in the premature degradation of corneodesmosomal cadherins. SCTE and SCCE expression was extended to the cell layers where Dsg1 and Dsc1 immunostaining was reduced. In contrast, a subset of six patients with normal epidermal protease activity or residual LEKTI expression displayed apparently normal cadherin expression and less severe disease manifestations. This suggests a degree of correlation between cadherin degradation and clinical severity. This work further supports the implication of premature corneodesmosomal cadherin degradation in the pathogenesis of NS and provides evidence for additional factors playing a role in disease expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16628198     DOI: 10.1038/sj.jid.5700284

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  44 in total

Review 1.  Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases.

Authors:  Akiharu Kubo; Keisuke Nagao; Masayuki Amagai
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

Review 2.  Involvement of corneodesmosome degradation and lamellar granule transportation in the desquamation process.

Authors:  Akemi Ishida-Yamamoto; Mari Kishibe
Journal:  Med Mol Morphol       Date:  2011-03-23       Impact factor: 2.309

3.  Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing.

Authors:  Chrystelle Bonnart; Céline Deraison; Matthieu Lacroix; Yoshikazu Uchida; Céline Besson; Aurélie Robin; Anaïs Briot; Marie Gonthier; Laurence Lamant; Pierre Dubus; Bernard Monsarrat; Alain Hovnanian
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

4.  Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts.

Authors:  Wei-Li Di; Fernado Larcher; Ekaterina Semenova; Gill E Talbot; John I Harper; Marcela Del Rio; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

5.  LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.

Authors:  Celine Deraison; Chrystelle Bonnart; Frederic Lopez; Celine Besson; Ross Robinson; Arumugam Jayakumar; Fredrik Wagberg; Maria Brattsand; Jean Pierre Hachem; Goran Leonardsson; Alain Hovnanian
Journal:  Mol Biol Cell       Date:  2007-06-27       Impact factor: 4.138

Review 6.  Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders.

Authors:  Matthias Schmuth; Robert Gruber; Peter M Elias; Mary L Williams
Journal:  Adv Dermatol       Date:  2007

Review 7.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

8.  Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis.

Authors:  Anna C Thomas; Daniel Tattersall; Elizabeth E Norgett; Edel A O'Toole; David P Kelsell
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 9.  Protease and protease-activated receptor-2 signaling in the pathogenesis of atopic dermatitis.

Authors:  Sang Eun Lee; Se Kyoo Jeong; Seung Hun Lee
Journal:  Yonsei Med J       Date:  2010-11       Impact factor: 2.759

10.  Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.

Authors:  Anaïs Briot; Céline Deraison; Matthieu Lacroix; Chrystelle Bonnart; Aurélie Robin; Céline Besson; Pierre Dubus; Alain Hovnanian
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.